Norman Feinsmith, MD
Cardiovascular Disease · Philadelphia, PANPI 1659303949
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $94,371 of the $94,371 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Janssen Research & Development, LLC. Reporting peaked in 2022 at $20,150 and has fallen 68.7% since, to $6,313 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $1097.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$94K
What the payments were for
- Consulting fees$94,371100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 86 | $94,371 |
How this compares
$94,371 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 292 | $368,931 |
| XareltoRivaroxaban | 118 | $123,490 |
| EntrestoSacubitril/Valsartan | 47 | $68,012 |
| MultaqDronedarone Hcl | 15 | $29,580 |
| JardianceEmpagliflozin | 22 | $22,812 |
| Repatha SureclickEvolocumab | 26 | $15,931 |
| Metoprolol Succinate | 545 | $9,620 |
| Praluent PenAlirocumab | 18 | $8,176 |
| Atorvastatin Calcium | 338 | $4,778 |
| Rosuvastatin Calcium | 214 | $4,225 |
| Ezetimibe | 89 | $2,915 |
| Ranolazine ErRanolazine | 15 | $2,815 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 49 | $2,042 |
| Valsartan | 41 | $1,944 |
| Amlodipine Besylate | 237 | $1,586 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.